1.
UKPDS Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853
2.
Gray A, Raikou M, McGuire A et al (2000) Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). BMJ 320:1373–1378
3.
UKPDS Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ 317:703–713
4.
UKPDS Group (1998) Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes (UKPDS 40). BMJ 317:720–726
5.
UKPDS Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854–865
6.
Clarke P, Gray A, Adler A et al (2001) Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51). Diabetologia 44:298–304
7.
Torrance GW (1986) Measurement of health state utilities for economic appraisal: a review. J Health Econ 5:1–30
8.
NICE (2004) Guide to the methods of technology appraisal. National Institute for Clinical Excellence, London
9.
UKPDS Group (1991) UK Prospective diabetes study VIII: study design, progress and performance. Diabetologia 34:877–890
10.
Netten A, Curtis L (2003) Unit costs of health and social care 2003. Personal Social Services Research Unit, Canterbury, Kent (University of Kent)
11.
Gray A, Clarke P, Farmer A, Holman R (2002) Implementing intensive control of blood glucose concentration and blood pressure in type 2 diabetes in England: cost analysis (UKPDS 63). BMJ 325:860
12.
Clarke P, Gray A, Legood R, Briggs A, Holman R (2003) The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS 65). Diabetes Med 20:442–450
13.
HM Treasury (2003) The green book: appraisal and evaluation in central government: treasury guidance. The Stationery Office, London
14.
UKPDS Group (1999) Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care 22:1125–1136
15.
DCCT (1996) Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. The diabetes control and complications trial research group. JAMA 276:1409–1415
16.
Clarke P, Gray A, Holman R (2002) Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 22:340–349
17.
Clarke P, Gray A, Briggs A et al (2004) A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom prospective diabetes study (UKPDS) outcomes model (UKPDS 68). Diabetologia 47:1747–1759
18.
Brown JB, Russell A, Chan W, Pedula K, Aickin M (2000) The global diabetes model: user friendly version 3.0. Diabetes Res Clin Pract 50:S15–S46
19.
Hougaard P (2000) Analysis of multivariate survival data (statistics for biology and health). Springer, Berlin Heidelberg New York
20.
Van Hout B, Al MJ, Gordon GS, Rutten FF (1994) Costs, effects and C/E-ratios alongside a clinical trial. Health Econ 3:309–319
21.
Stinnett AA, Mullahy J (1997) The negative side of cost-effectiveness analysis. JAMA 277:1931–1932
22.
Rawlins MD, Culyer AJ (2004) National Institute for Clinical Excellence and its value judgments. BMJ 329:224–227
23.
CDC Group (2002) Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 287:2542–2551
24.
Audit Commission (2000) Testing times: a review of diabetes services in England and Wales. Audit Commission, London